

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 October 2020 (22.10.2020)



(10) International Publication Number
WO 2020/212581 A1

(51) International Patent Classification:

A61P 35/00 (2006.01) A61P 37/00 (2006.01)
A61K 31/445 (2006.01) C07D 211/24 (2006.01)
A61K 31/4545 (2006.01) C07D 401/12 (2006.01)

(21) International Application Number:

PCT/EP2020/060879

(22) International Filing Date:

17 April 2020 (17.04.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1905520.1 18 April 2019 (18.04.2019) GB

(71) Applicant: MODERN BIOSCIENCES LIMITED

[GB/GB]; The Walbrook Building, 25 Walbrook, London
Greater London EC4N 8AF (GB).

(72) Inventors: PATEL, Lisa; Modern Biosciences Limited,

The Walbrook Building, 25 Walbrook, London Greater
London EC4N 8AF (GB). SMITH, Stephen Allan; Stort
MedChem Consulting Ltd, 67 Langham Gardens, Lon-
don Greater London N21 1DL (GB). COLLINGWOOD,
Stephen Paul; SPCR Consulting Limited, 16 Heyworth
Ride, Haywards Heath, West Sussex Sussex RH16 4TN
(GB).

(74) Agent: MEWBURN ELLIS LLP; Aurora Building, Counterslip Bristol BS1 6BX (GB).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE



(57) Abstract: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain N-acyl-{4-[(4-aryl-phenyl)sulfonylmethyl]piperidine} compounds of the following formula (collectively referred to herein as NASMP compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, e.g., multiple myeloma, diffuse large B-cell lymphoma, acute myeloid leukemia, eosinophilic leukemia, glioblastoma, melanoma, ovarian cancer, chemotherapy resistant cancer, radiation resistant cancer, inflammatory arthritis, rheumatoid arthritis, psoriatic arthritis, psoriasis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus (SLE), lupus nephritis, asthma, chronic obstructive pulmonary disease (COPD), Hidradenitis suppurativa, autoimmune hepatitis, etc. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.

WO 2020/212581 A1